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Abstract 
 
 
Ghrelin  increases  food  intake  and  decreases  energy  expenditure,  promoting  a  positive 
energy balance. We observed a single case of serious hypothermia during sustained ghrelin 
treatment in a male subject, suggesting that ghrelin may play a role in the regulation of body 
temperature. We therefore investigated the effect of ghrelin treatment on body temperature in 
rodents and humans under controlled conditions. Intriguingly, we could demonstrate ghrelin 
binding in axon terminals of the medial preoptic area of the hypothalamus located in the 
vicinity of cold-sensitive neurons. This localization of ghrelin receptors provides a potential 
anatomical basis for the regulation of body temperature by ghrelin. However, our follow-up 
studies also indicated that neither a chronic i.c.v. application of ghrelin in rats, nor a single 
s.c. injection under cold exposure in mice resulted in a relevant decrease in body core 
temperature. In addition, a four-hour intravenous ghrelin infusion did not decrease body 
surface temperature in healthy humans. We concluded that while there is a theoretical 
molecular  basis  for  ghrelin  to  modify  body  temperature  in  mammals,  its  magnitude  is 
irrelevant under physiologic circumstances. Hypothermia is not likely to represent a serious 
risk associated with this agent and pathway. 
 
Keywords: ghrelin, hypothermia, medial preoptic area, thermogenesis, body temperature, 
cold exposure 
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1  Introduction 
 
 
Energy balance is achieved by constant adjustment of energy intake and energy expenditure 
as required by changing metabolic demands of the mammalian organism. While energy 
supply is provided by food intake, total energy expenditure results from the cumulative 
effects of resting metabolic rate (resting thermogenesis), thermic effect of food, spontaneous 
locomotor activity (SPA, or non-exercise activity thermogenesis, NEAT) and exercise as well 
as facultative thermogenesis (in case of demand e.g. during cold exposure). While obesity 
researchers have studied these individual components intensely during recent decades to 
understand how chronic energy balance and, consequently, body fat mass are regulated, the 
exact molecular underpinnings of these control processes remain to be elucidated. 
 
The gastrointestinal peptide hormone, ghrelin, has been reported to increase food intake [1- 
 
3] and to impair nutrient partitioning [3], thereby leading to positive energy balance and 
increased body fat mass [1, 3]. However, it remains unclear to which extent ghrelin directly 
acts to decrease total energy expenditure in rodents [1, 3-5]. Obviously, single components 
of energy expenditure appear to be affected by ghrelin action. A single i.c.v. injection of 
ghrelin can decrease spontaneous locomotor activity (SPA) in rats for duration of 24h [6, 7]. 
In addition, single i.c.v. injections of ghrelin or growth hormone secretagogues in rats were 
shown to transiently decrease body core temperature for the first 1-2 h after administration 
[2] and to decrease temperature and sympathetic activity in brown adipose tissue [8]. 
However, it is still unclear whether ghrelin affects thermogenesis in humans and via which 
specific pathways in the central nervous system ghrelin might induce these changes. 
 
We observed a single case of severe hypothermia in a patient with cancer cachexia while 
receiving a pharmacological dose of ghrelin treatment. We subsequently investigated if there 
was an obvious neuroanatomical basis for such an event and whether exogenous ghrelin 
administration could induce hypothermia, performing a series of studies in rodents and in 
healthy humans. 
 
 
 
 
2  Materials and Methods 
 
 
2.1 Human Studies 
 
2.1.1 Case report of hypothermia during sustained ghrelin treatment 
 
 
A single case of hypothermia was observed during performing the study “Individual Dose- 
Escalated  bi-Daily  Subcutaneously  Ghrelin  in  Cancer  Cachexia:  a  Phase  I/II  Study”, 
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(ClinicalTrials.gov  Identifier:  NCT00933361).  The  primary  objective  of  the  study  was  to 
investigate the dose effect of natural ghrelin (manufactured by Bachem, Weil am Rhein, 
Germany; filled by Clinalfa, Läufelingen, Switzerland; [9]) on nutritional intake (the minimal 
dose for maximal nutritional intake; MD-MANI) and to identify the maximally tolerable dose 
(MTD) in patients with cancer cachexia. The starting dose of 32 μg/kg was found to be safe 
to use in subjects with cancer cachexia from our previously published study [9]. The dose 
escalation was 50% between doses for the first 4 dose levels (32, 48, 72, 108 μg/kg) and 
25% between the 4th  and the 5th  dose level (135, 169 μg/kg). The volume of ≥5ml (20mg 
 
ghrelin) was defined as one criterion for MTD. Plasma levels for total and active ghrelin 
during this study were determined by Lincoplex RIA (Millipore, GHRT-89HK and GHRA- 
88HK, respectively) 
 
 
 
 
 
 
2.1.2 Continuous ghrelin infusion in humans 
 
 
Subjects: Healthy volunteers between the ages of 18 and 55 years with a BMI between 18 
and 29 kg/m2  were recruited from the greater Cincinnati area. Subjects with a history or 
clinical  evidence  of  impaired  fasting  glucose  or  diabetes  mellitus,  recent  myocardial 
infarction, congestive heart failure, active liver or kidney disease, growth hormone deficiency 
or excess, neuroendocrine tumor, anemia or who were on medications known to alter insulin 
sensitivity were excluded. 
 
All study procedures were conducted at the Cincinnati Children’s Medical Center Clinical 
Translation Research Center (CTRC). All study participants gave informed consent for the 
study by signing a form approved by University of Cincinnati Institutional Review Board. 
 
Experimental protocol: Subjects arrived at the CTRC between 0700 and 0730 after a 10-12 
hour fast for three separate experiments. Intravenous (i.v.) catheters were placed in veins of 
both forearms for blood sampling and infusion of ghrelin. The arm with the sampling catheter 
was heated to 55° to arterialize venous blood. A skin temperature sensor (GE Healthcare, 
WI, U.S.A.) was placed in the axilla of study subjects with transpore tape. The sensor was 
connected to a bedside vital signs monitor (Dash 4000, GE Healthcare, WI, U.S.A.) for 
display and data storage. Body surface temperature was measured continuously and was 
recorded every 5 minutes during the study. Adverse events were assessed and recorded by 
study staff at the CTRC during the study and by study investigators outside of the study unit. 
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Total immunoreactive ghrelin was measured by radioimmunoassay (Millipore, Billarica, MA, 
U.S.A.). The lower and upper limits of detection were 27 and 1765 pM respectively, and the 
intra- and inter-assay coefficients of variation were 6.4 and 16.3%, respectively. 
 
The study was originally designed to study the effect of exogenous ghrelin administration on 
glucose homeostasis in humans. A frequently sampled i.v. glucose tolerance test (FSIGT) 
was performed during ghrelin infusion to measure insulin secretion and insulin sensitivity 
(presented as poster at 46th EASD Meeting 2010). Synthetic human acylated ghrelin was 
obtained from Bachem AG (Rubendorf, Switzerland).   The authenticity of the peptide was 
verified by mass spectrometry, the purity was > 95%, and reconstituted material was sterile 
and free of detectable pyrogens. On each morning of the three study days, either saline or 
synthetic ghrelin dissolved in sterile saline solution was infused at doses of 0.2 or 0.6 
nmol/kg/hr (equivalent to 0.5 or 2 µg/kg/hr) for a total of 225 minutes. Specifically, following 
45 minutes of ghrelin infusion, previously shown to be sufficient to bring plasma ghrelin levels 
to a steady state [10] subjects received an i.v. bolus of glucose (11.4 g/m2 body surface area) 
over 60 seconds at the initiation of the FSIGT (time 0).  At time 20 minutes subjects received 
an i.v. infusion of insulin (0.025 µU/kg) over 5 minutes.   Blood samples were collected in 
EDTA containing tubes at intervals varying between 1 to 20 minutes during the duration of 
the FSIGT (total of 180 minutes).   The order of ghrelin infusions was randomized using a 
computer generated randomized number set (http://www.randomizer.org), and study visits 
were separated by at least five days. 
 
2.2 Rodent Studies 
 
 
2.2.1 Animals 
 
 
All experiments were performed according to the federal guidelines of the Brandenburg 
Ministry of Agriculture, Environment Protection and Regional Planning and the Institutional 
Animal Care and Use Committee of Yale University. Male Wistar rats and male C57BL/6 
mice were purchased from Charles River WIGA GmbH (Sulzfeld, Germany) at the age of 5 
weeks  and  10  weeks,  respectively.  Animals  were  maintained  singly  under  standard 
conditions (25°C, 12h:12h dark:light cycle) receiving standard chow (sniff RIM-H, V1534-000, 
Soest, Germany) and tab water ad libitum, unless otherwise stated. Three different sets of 
experiments were performed 
 
2.2.1 Immunohistochemistry and ghrelin binding assay 
 
 
Immunofluorescence labeling for ghrelin was carried out using the same ghrelin antisera and 
secondary antisera as described in our earlier studies [11]. Double labeling for ghrelin and 
c-fos was done in rats exposed to 4°C ambient temperature for 6 hours using avidin-biotin 
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peroxidase and peroxidase anti-peroxidase methods, and, the tissue-bound peroxidase was 
visualized by a nickel-diaminobenzidine reaction as described in our earlier studies. [12]. 
Ghrelin binding to hypothalamic preoptic area sections was carried out as described in our 
earlier studies [11]. 
 
 
 
2.2.2 Chronic i.c.v. Ghrelin Infusion in Rats 
 
 
This experiment was designed to evaluate if chronic ghrelin infusion for six days induces a 
sustained  decrease  in  body  core  temperature  in  male  Wistar  rats.  In  addition,  gross 
locomotor activity and feeding patterns were constantly monitored. Body temperature and 
gross locomotor activity were monitored using biotelemetry (see details in 2.2.5). Feeding 
behavior was measured using the TSE Drinking & Feeding Monitoring System (TSE GmbH, 
Bad Homburg, Germany). This system permits the measurement of feeding behavior online 
for several days or weeks. Feeding baskets are attached to a scale, which monitors weight 
changes due to consumption of food by the laboratory animal during the experiment. 
 
Rats were given two weeks for acclimation to housing conditions and were handled daily. 
Rats were then adapted to cages for the measurement of food intake for four consecutive 
days. Two weeks later, all rats received an intraperitoneal implanted transponder for the 
measurement  of  body  temperature  and  gross  locomotor  activity.  Rats  were  allowed  to 
recover for at least 7 days until regaining their pre-surgical body weight. Then rats were 
subjected to intracerebral implantation (right ventricle: AP: −0.080, L:-0.140 D: −0.350, [13]) 
of a permanent cannula (Osmotic Pump single Connector Cannula 322OP/Spc, gauge 22, 
length below pedestal 5 mm, Plastics One Inc., Roanoke, VA,USA) with their heads securely 
held in a stereotaxic frame (David Kopf instruments, Tujunga, CA, USA). For implantation, 
rats were anesthetized with ketamin hydrochloride (100mg/kg, Ketamin Graeub, A. Albrecht 
GmbH,  Aulendorf,  Germany)/xylazine  hydrochloride  (10mg/kg,  Rompun®,  Bayer  Vital 
GmbH, Leverkusen, Germany) given intraperitoneally (i.p.). The cannula was connected via 
PE tubing to an osmotic minipump (ALZET model 2002, 0.5 µl/h, DURECT Corporation, 
Cupertino, CA, USA) filled with either saline (Sigma-Aldrich) or rat ghrelin (generated in- 
house by the DiMarchi laboratory), which was subcutaneously (s.c.) implanted at the same 
time. The connecting tube was filled with saline and had a length of 21.8 cm corresponding 
to a pumped volume sufficient for 5 days. This period served to give rats time for recovery 
from the surgery before ghrelin treatment started. Ghrelin concentration in the pump was 
adjusted to the pump rate for releasing 2.5nmol/d for 6 days. This dose was shown to be 
effective  to  increase food  intake  and  body weight  after  a one-week  treatment  [3]. The 
cannula was fixed using dental cement (Stoelting Co. Illinois, USA) and the skin was closed 
using resorbable suture (PGA Resorba, Resorba, Nürnberg, Germany). After surgery rats 
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received a single subcutaneous (s.c.) injection of Buprenorphin (0.05mg/kg, Temgesic®, 
Essex Pharma GmbH Munich, Germany) and Carprofen (5mg/kg, Rimadyl®, Pfizer GmbH, 
Karlsruhe,  Germany)  for  analgesic  treatment.  Proper  placement  of  the  cannula  was 
confirmed in the end of the experiment at time of sacrifice by injecting 5 µl of bromophenol 
blue into the cannula. Only animals with proper staining of the lateral ventricle were included 
in the data analysis. Increase in food intake and body weight in response to ghrelin treatment 
was used as a second marker for proper cannula placement.  Using these two markers, 7 
saline-treated and 6 ghrelin-treated rats were identified as having successful cannulation and 
were included in data analysis. 
 
 
2.2.3 Acute Peripheral Ghrelin Injection in Mice 
 
 
This experiment was performed to investigate whether peripherally injected ghrelin affects 
body core temperature as well as locomotor activity, total energy expenditure (TEE) and 
respiratory quotient (RQ). To force the thermogenic capacity of body temperature regulation, 
mice were subjected to acute non-acclimated cold exposure (4°C) for 23h following rat 
ghrelin injection (treatment day). For comparison to basal conditions, all mice were injected 
with saline (100 µl) i.p. and measured for the above mentioned parameters at 21°C ambient 
temperature 2 days before cold exposure was applied (control day), leaving one resting day 
between measurements. 
 
Body  temperature  and  gross  locomotor  activity  were  monitored  using  the  biotelemetry 
system as described under 2.2.5 After 2 weeks of recovery from the implantation surgery, 
mice were then injected with 100 µl of saline i.p. at 3 hours before lights off followed by 
constant monitoring of body core temperature, gross locomotor activity, total energy 
expenditure (TEE) and respiratory quotient for 23h at 21°C ambient temperature, these 
measurements serving as baseline (control day). After one day of rest mice were i.p. injected 
with  100  µl  of  either  saline  or  mouse  ghrelin  (10  mg/kg,  Bachem  AG,  Rubendorf, 
Switzerland) at 3 hours before lights off followed by constant monitoring of the above 
mentioned parameters for 23h at cold ambient temperature (4°C) which was applied by 
placing the mouse cages into a cold chamber (treatment day). 
 
Acute peripheral administration of ghrelin can increase food intake [1]. However, food intake 
and nutrient absorption are accompanied by increased substrate turnover, which results in 
increased  energy  expenditure  and  body  temperature  (postprandial  thermogenesis).  To 
control for the thermogenic effect of food consumption, half of the mice from both treatment 
groups were kept without food for the first 5 hours following injection.  Therefore, 4 treatment 
groups were used for the measurement at cold ambient temperature: saline treated mice with 
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ad libitum access to food, ghrelin treated mice with ad libitum access to food, saline treated 
mice without access to food for 5 hours following injection and ghrelin treated mice without 
access to food for 5 hours following injection. Data shown for measurements at 21°C 
represent all mice (n=40), while data shown for measurements at 4°C represent 10 mice per 
treatment group. Most of the effects were only present during the first 5 hours after ghrelin 
treatment. Therefore, most data presented cover only this time period. 
 
2.2.4 Measurement of energy expenditure 
 
 
Energy expenditure and respiratory quotient were measured by indirect calorimetry using a 
self-constructed system equipped with the gas analyzing system Advance Optima from ABB 
AG (Mannheim, Germany, formerly Hartmann & Braun). The system provides one 
measurement every six minutes per cage. Mice were adapted to respiratory cages for two 
days prior to baseline measurement at 21°C. Mice were kept in respiratory cages until 
completion of measurements at 4°C. 
 
2.2.5 Implantation of biotelemetry transponders 
 
 
Body core temperature and gross locomotor activity of mice and rats were measured using 
biotelemetry (Mini Mitter Co., Inc., Bend, OR, USA). This system requires implantation of 
transponders into the abdominal cavity and the animal cage to be placed on a receiver. 
Signal frequency (translating into body core temperature values) and localization of the 
transponder  signal  on  the  receiver  (interpreted  as  movement)  were  measured  every  6 
minutes being in line with EE measurements for the cold exposure experiment. Mice and rats 
were implanted with transponders under ketamin hydrochloride (1 μl/g, Ketamin Graeub, A. 
Albrecht GmbH, Aulendorf, Germany)/xylazine hydrochloride (0.2 μl/g, Rompun®, Bayer Vital 
GmbH, Leverkusen, Germany) anaesthesia. The abdominal cavity was closed using 
resorbable suture (PGA Resorba, Resorba, Nürnberg), the skin was closed with clips that 
were removed 1 week after surgery. Animals received a single i.p. analgesic treatment of 
Carprofen  (5mg/kg,  Rimadyl®,  Pfizer  GmbH,  Karlsruhe,  Germany)  following  surgery. 
Animals were allowed to recover for at least one (rats) or two weeks (mice) following 
transponder implantation before the start of the experiment. 
 
2.3 Statistics 
 
 
Animal studies: In chronic i.c.v. ghrelin experiments, food intake and body temperature were 
calculated as hourly means, while locomotor activity was presented as hourly sum. Data for 
plasma  ghrelin  concentration  was  not  normally  distributed  and  did  not  meet  variance 
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homogeneity requirement. Therefore, the difference between the saline and ghrelin treated 
groups was compared using a non-parametric Mann-Whitney-U test. 
 
In acute peripheral ghrelin experiments, the most prominent effects were observed during the 
 
5 hours of food deprivation following injection. Therefore, most parameters were presented 
only for the first 5 hours following treatment. The indirect calorimetry measurements were 
presented as group means of values measured every 6 min. Food intake was measured 24 
hours after injection. Differences between groups were analyzed using analysis of Variance 
(ANOVA), and LSD was used as post-hoc test for multiple comparisons. All results are 
expressed as mean ± SEM.  Significance was assumed at P<0.05. Analysis was performed 
using SPSS 8.0 (SPSS Inc., 1998, Chicago, IL, USA). 
 
 
Clinical study in humans: Data were analyzed using ANOVA with three treatment levels 
(control, and ghrelin infusion rates of 0.2 and 0.6 nmol/kg/hr) and time of sampling being the 
repeated measure.  Dependent variable was body surface temperature.  Data were analyzed 
using GraphPad Prism version 5.0 (GraphPad Software). 
 
 
 
 
3  Results and Discussion 
 
 
3.1 A  single  case  of  serious  hypothermia  in  response  to  sustained  ghrelin 
treatment in a male subject (see supplemental material for details) 
 
A 66 year-old male was diagnosed with locally advanced (infiltration of stomach) and 
metastatic  pancreatic  adeno-carcinoma  one  year  before  ghrelin  study  started.  He  was 
treated with tumor-debulking surgery and additional gastrectomy, splenectomy, and 
cholecystectomy, followed by nine months chemotherapy with gemcitabine and capecitabine. 
A break in chemotherapy at month five resulted in tumor progression. He had no relevant co- 
morbidities. He lost 9.2% weight during the last 6 months before ghrelin treatment. Two 
weeks  prior  to  study  begun,  symptoms  that  could  impact  nutrition  (e.g.  constipation, 
abdominal pain and dietary) were treated with appropriate medications. 
 
At baseline, the patient’s BMI was 18 kg/m2, blood pressure was 92/55 mmHg in supine 
position, heart rate  was 71 beats per minute (bpm), body temperature was 36.6°C (ear), 
morning fasting level of active ghrelin was 26 pg/ml, while total ghrelin was 432 pg/ml. His 
renal and hepatic function and electrolytes were normal. He received dose levels 1-4 per 
protocol (two days per dose level, with two s.c. injections per day).  There was a washout 
period of 1-2 days between doses. The patient tolerated the treatment well.  Despite the lack 
of improvement regarding nutritional intake, he had improved appetite, alertness and mood 
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based on subjective assessment using narratives and qualitative content analysis. 
Pharmacokinetics of ghrelin were measured on days 1 (dose level 1), 8 (dose level 3), and 
15 (dose level 5). Pre-injection levels for active ghrelin and total ghrelin were 18 and 408 
pg/ml (day 1), 20 and 464 pg/ml (day 8), and 52 and 897 pg/ml (day 15), respectively. Peak 
values at 45 minutes were 190 pg/ml and 2685 pg/ml, ≥1800 pg/ml (above upper detection 
limit) and 2694 pg/ml, and ≥1800 pg/ml and 2706 pg/ml, respectively. Since no MD-MANI 
and no MTD was achieved, dose level 5 (6750 µg, 1.7ml) was given on day 15 in the 
morning at the hospital.  The patient was stable and had normal vital signs. The second dose 
was given by patients’ spouse at home in the evening of the same day. On day 16 the third 
dose  of  level  5  was  given  s.c.  at  home  at  12:45.  Fifteen  minutes  into  the  ghrelin 
administration the patient started to experience hot flashes and acute tiredness that lasted 
for 30 minutes. Then he reported that he felt cold. His heart rate was 68 bpm and at 14:30 
his temperature was 33°C. The spouse gave him granulated sugar to treat suspected 
hypoglycemia. The patient did not have shivering or chills and remained alert and fully 
conscious without impaired cognition. At 15:30 patient was seen by the general practitioner 
and had a low blood pressure of 71/55 mmHg, low body temperature of 32.6°C on 
examination. No clinical signs of acute cardiac ischemia or heart failure were found. Advice 
was given to administer 0.9% normal saline intravenously, to warm the patient and to transfer 
him to the hospital. Upon arrival at the Oncology clinic at 16:25, his blood pressure was 
100/70 mmHg, heart rate 48 bpm, temperature 33.6°C (auricular), oxygen saturation 88%, 
and  blood glucose 6.9 mmol/l. There was no biochemical evidence of organ failure or acute 
infection. The patient was tired, but able to communicate. A blood sample was drawn one 
hour later at the emergency room for analysis of ghrelin levels. Blood sample was stored at - 
80°C after collection but was not treated with protease inhibitors as for other samples due to 
the unforeseen unfolding of events. Under these circumstances, active ghrelin was 86 pg/ml; 
total ghrelin level was 4027 pg/ml. 
 
The patient received continuous normal saline infusion, a warming blanket, and 8 mg of 
dexamethasone (intravenously). The patient felt hungry at 17:15 and felt better after eating 
soup. His temperature and other vital signs continued to improve with time. At 19:45 the 
patient felt significantly better. His vital signs slowly normalized.  He was later transferred to 
the inpatient Oncology ward for observation and went home the day after. 
 
To summarize, in this male subject with pancreatic adeno-carcinoma associated cachexia, 
hypothermia occurred in the late stage of sustained ghrelin treatment with escalating doses. 
After administering the third injection of   highest ghrelin dose (level 5 at 6,750 µg) on day 15, 
the patient’s body temperature dropped from a subjectively normal range down to 33°C 
within two hours after ghrelin injection was given. The patient remained hypothermic (33 - 
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34°C) for a total of three hours before his temperature started to rise again. The decrease in 
temperature was accompanied by only moderate changes in blood pressure, and the patient 
showed no signs of organ failure or other associated pathology. Intriguingly, the low body 
temperature was associated with a high plasma concentration of total ghrelin that was about 
150% above the level at 45 min after ghrelin injection was given. 
 
 
Based on these observations we revisited the question, if ghrelin may be a potent and direct 
regulator of body temperature. Evidence exists that that ghrelin may decrease body 
temperature in rodents. When ghrelin was acutely injected into the brain, body core 
temperature decreases transiently for the first 1-2 h after administration [2]. Furthermore, 
third ventricular administration of ghrelin transiently decreased the temperature of brown 
adipose tissue (BAT) and suppressed BAT sympathetic nerve activity in rats [8]. The latter 
phenomenon indicates diminished energy expenditure due to decreased rate of facultative 
thermogenesis. However, reports regarding a relevant ghrelin induced decrease in energy 
expenditure are inconsistent [1, 3-5]. Based on our observation of a case of severe 
hypothermia following high-dose ghrelin administration, we investigated the role of ghrelin in 
body temperature regulation. We first examined whether there was a theoretical 
neuroanatomical basis for ghrelin receptor activation to affect the central nervous system 
(CNS) circuitry known to control body temperature. 
 
3.2 Ghrelin binds to GHS-R in the medial preoptic area (MPOA) 
 
 
The  MPOA  of  the  hypothalamus  is  believed  to  represent  the  key  area  for  the  central 
regulation of autonomic thermo-effector responses [14]. When stimulated, warm-sensitive 
MPOA neurons trigger heat defense mechanisms, whereas when inhibited, these neurons 
trigger cold defense mechanisms [14]. Thereby the MPOA is a central element to the control 
of body core temperature. 
 
We detected ghrelin binding and ghrelin-immunoreactivity in the rat medial preoptic area 
(Figure 1). In addition, ghrelin-immunolabeled axon terminals contacted neurons that 
expressed  c-fos  in  response  to  cold  exposure.  These  data  suggest  that  hypothalamic 
neurons expressing ghrelin immunoreactivity are in anatomical position to participate in the 
regulation of core body temperature by the MPOA. 
 
The  precise  mechanism  of  temperature  regulation  has  not  been  fully  elucidated.  It  is 
assumed that the MPOA in the hypothalamus is a major site for integrating and controlling 
body core temperature regulation [14, 15]. Efferent neuronal projections form the MPOA to 
the periphery are sympathetic nerves extending to skin blood vessels, skeletal muscle and 
BAT [14]. Ghrelin has been shown to influence sympathetic outflow to BAT by decreased 
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sympathetic nerve activity in BAT [8] and chronic i.c.v. ghrelin infusion decreased expression 
of UCP1 mRNA in BAT of rats that were either fed ad libitum or that were pair-fed to control 
rats [3]. Our immunohistochemical results however indicate that ghrelin may also regulate 
body temperature at a higher central level by binding to receptors in the MPOA. In addition, 
the reported ghrelin binding to cell bodies in the MPOA coincide with the expression of the 
ghrelin receptor GHS-R1a in this hypothalamic area [16, 17], indicating that ghrelin may play 
a role in body temperature regulation. However, our data are descriptive in nature, and it is 
not yet known which specific type of neurons ghrelin is binding to in the MPOA, or if and how 
ghrelin elicits a change in their activity or thermoregulating output by binding to MPOA 
neurons lying adjacent to thermosensitive neurons. 
 
Nevertheless, our data show that there is a theoretical neuroanatomical basis for ghrelin 
induced activation of neurons in the MPOA - a key CNS area regulating body temperature. 
To further elucidate the physiologic role of ghrelin for body temperature regulation we next 
performed in vivo experiments in rodents to study the chronic and acute effects of ghrelin on 
body temperature regulation in the context of overall changes in energy balance. 
 
3.3 Ghrelin does not induce significant hypothermia in rodents 
 
 
3.3.1 Chronic central ghrelin infusion is ineffective in decreasing body temperature 
 
 
Centrally administered ghrelin was reported to stimulate lipogenesis in white adipose tissue 
and liver in rats after a one week treatment to facilitate storage of incoming nutrients as fat 
[3]. Since acute i.c.v. ghrelin injection transiently decreased body temperature in rats [2], we 
intended to investigate whether a chronically increased ghrelin level in the hypothalamus 
would induce a persistent decrease in body core temperature thereby contributing to energy 
storage. To test this hypothesis, we chronically infused rats with ghrelin (2.5 nmol/day) for 6 
days via osmotic minipumps into the left lateral ventricle. The ghrelin dose used was reported 
to promote food intake and adiposity in rats during a 6-day treatment period [3]. The ghrelin 
infusion significantly increased food intake and body weight starting from the second day of 
treatment (Figures 2A and B) confirming that the ghrelin preparation was bioactive. However, 
this treatment did not affect body core temperature or gross locomotor activity (Figures 3A 
and B). Taking the lack of effect on body temperature with chronic ghrelin i.c.v. infusion 
together with the previously reported decrease in body temperature with acute i.c.v. injection 
[2] it appears that a hypothermic effect of ghrelin may require an acute rise in ghrelin level 
above a certain threshold. Consistently, lower ghrelin concentrations appear to be insufficient 
to alter body temperature. This observation makes physiological sense since ghrelin is 
secreted in a pulsatile manner and peaks before meals [18-20]. A ghrelin induced drop in 
body temperature prior to a meal may prepare the organism better for an efficient absorption 
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and storage of incoming nutrients and energy. Also, ghrelin-induced hypothermia may be 
more easily inducible under conditions of lower environmental temperature. To test these 
hypotheses we  next  investigated the potential hypothermic effect  of a single peripheral 
ghrelin injection in mice under challenged conditions such as cold exposure. 
 
3.3.2 A single peripheral ghrelin injection is ineffective in decreasing body temperature 
 
 
We subjected normal male mice to a single peripheral (i.p.) injection of ghrelin (10 mg/kg) 
and measured body core temperature, energy expenditure, locomotor activity, food intake, 
and  respiratory  quotient  subsequently  for  24  hours.  To  test  the  robustness  of  the 
hypothermic response to the acute rise in ghrelin level, we challenged the thermoregulatory 
system by exposing the injected mice to cold ambient temperature (4°C). Changes in the 
parameters of energy balance were compared to another group of mice treated with saline 
under the same  experimental conditions The same parameters were also  measured at 
normal temperature (21°C) following saline injection in the same mice (basal condition). In 
order to measure the contribution of the thermic effect of food, we removed food from a 
group of mice for 5 hours immediately following ghrelin or saline injection. We compared 
changes in body temperature and energy expenditure in 4 groups of mice that were exposed 
to cold ambient temperature: saline treated mice with ad libitum access to food, ghrelin 
treated mice with ad libitum access to food, saline treated mice without access to food for 5 
hours following injection and ghrelin treated mice without access to food for 5 hours following 
injection. 
 
Cold exposure increased 24h food intake in all treatment groups as compared to normal 
temperature exposure (Figure 4). Mice receiving ghrelin with ad libitum access to food 
ingested significantly more calories under cold ambient temperature conditions than the other 
treatment groups indicating bioactivity of the ghrelin preparation. Ghrelin treatment failed to 
increase food intake when food was supplied beginning at 5 h after injection, possibly due to 
the short half-life of the ghrelin peptide [20]. Peripheral ghrelin administration transiently 
increased respiratory quotient when mice had access to food (Figure 6B), indicating 
immediate start of food uptake. Saline injected mice with ad libitum access to food increased 
respiratory  quotient  with  the  beginning  of  the  dark  phase,  when,  according  to  normal 
circadian rhythm, the majority of the food is usually consumed. Food deprivation for the 
duration of 5h following injection decreased respiratory quotient to a similar extent in saline 
and ghrelin treated mice. 
 
Our data suggest that changes in body core temperature were much more significantly 
influenced by the presence or absence of food than by ghrelin treatment (Figure 5B). Body 
core temperature decreased transiently for 2.5 hours after exposure to 4°C when mice had 
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ad libitum access to food, regardless of the type of treatment. Of note, ghrelin treated mice 
had slightly, but insignificantly lower body temperature after 1 hour. Interestingly, the cold 
induced decrease in body temperature was fully blocked by food deprivation. When mice 
were food deprived for 5 h following saline or ghrelin treatment, body temperature increased 
in concordance with increased locomotor activity similarly in saline and ghrelin treated mice 
(Figure 5D). As a result, this led to an increase in total energy expenditure in both food 
restricted  groups  (Figure  5F).  Increased  locomotor  activity  was  likely  an  indicator  for 
increased food seeking behavior due to cold induced increase in energy demands. Since 
ghrelin and saline injected animals responded similarly, it can be assumed that the drive to 
eat was increased in both food restricted groups due to cold exposure. Furthermore, food 
deprivation for 5 h following injection decreased respiratory quotient to a similar extent in 
saline and ghrelin treated mice. This likely indicates a shift toward preferential fat oxidation to 
ensure sufficient energy supply when food was not available and to meet the increased 
demand for thermogenesis when ambient temperature was low. Therefore, we speculate that 
the potential hypothermic effect of ghrelin is dependent on food availability and may be 
influenced by ambient temperature and food restriction. While there is evidence that ghrelin 
decreases sympathetic nerve activity [8], possibly via neuropeptide Y and agouti-related 
protein [8, 21-26], we were unable to show that this effect is associated with lowering body 
temperature in rodents. It is still possible that ghrelin may have lowered temperature in 
certain tissues or organs like BAT, liver or skin, which was not significant enough to be 
detected by changes in core temperature. In this context, the decrease in body core or BAT 
temperature after i.c.v. injection of ghrelin reported elsewhere [2, 8] may just represent a 
result or “by-product” of decreased sympathetic outflow to BAT. The extent to which 
temperature is reduced may depend on the ability of ghrelin to reach the central receptors, 
the timing of ghrelin injection, and the initial capacity for non-shivering thermogenesis at a 
given point in time and condition. Such details in experimental design may explain the 
discrepancy between reported temperature decreases and our results [2, 8]. 
 
3.1 Peripheral  ghrelin infusion  does  not  decrease  body surface  temperature in 
humans 
 
We subjected healthy subjects to a 225 min continuous intravenous (i.v.) infusion of either 
saline  or  ghrelin  in  doses  of  either  0.2  or  0.6  nmol/kg/hr  on  three separate  days  and 
measured body surface temperature for the whole infusion period. Sixteen healthy subjects 
(8 male and 8 females) aged 28.3  6.0 years with a BMI of 27.7  2.7 kg/m2 completed the 
study.  Steady-state levels of ghrelin in the plasma were reached after approximately 45 
minutes after the ghrelin infusion began. Ghrelin infusions at 0.2 and 0.6 pmol/kg/hr 
(equivalent to 0.5 and 2 g/kg/h respectively) raised steady-state plasma total ghrelin levels 
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to  2.4  and  6.7-fold  above  fasting  concentrations,  respectively.  Continuous  acyl  ghrelin 
infusion at 0.2 and 0.6 nmol/kg/hr had no effect on body surface temperature (p = 0.15) 
(Figure 7). The administration of glucose and insulin during the frequently sampled i.v. 
glucose tolerance test did not appear to alter body surface temperature either. Ghrelin 
infusion was well tolerated. The most common complaints during the infusion of ghrelin were 
hunger and warm sensation. No unexpected or serious adverse event occurred during the 
study. 
 
It is worth noting that the dose of ghrelin used in this study was much lower than the one 
used in the case report (< 800 g vs. 6750 g, respectively). The route of administration also 
differed between the two studies (i.v. infusion vs. s.c. injection as in the case report). The 
study subjects in this study were healthy, while the patient who suffered from hypothermia 
had terminal cancer of the digestive system. To our knowledge, data on chronic ghrelin 
treatment on body temperature regulation in humans is lacking. 
 
With the exception of the here reported single case of hypothermia that occurred following 
high dose, repeated, ghrelin injections, changes in body temperature related to ghrelin 
administration in humans have not been reported elsewhere.  Despite the existing evidence 
in rodents that ghrelin may lower body temperature following acute administration [2], 
decrease sympathetic outflow to BAT and decrease BAT temperature [8], a clear, direct and 
clinically relevant effect of ghrelin on body temperature regulation cannot be established 
based on our studies. 
 
 
4  Conclusions 
 
 
We have shown here that intriguingly there is ongoing ghrelin binding to GHSR-1a in the 
MPOA, a critical region for temperature regulation. This implies that there is a theoretical 
basis  for  potential  direct  regulation  of  body  core  temperature  by  ghrelin  in  mammals. 
However, under the several specific conditions studied here (e.g. ad libitum feeding, normal 
and cold ambient temperature exposure), ghrelin does not alter body temperature in rodents 
or humans. The here reported single case of hypothermia in a cancer patient might involve 
several coincided influencing factors. One of these factors could be the loss of vagal 
connection to the gut as a result of total gastrectomy and vagotomy that could result in 
disturbed ghrelin action on the autonomic nervous system. It is known that the ghrelin 
receptors are expressed in the nodose ganglion [27] indicating an important pathway 
connecting  the  central  and  peripheral  (gastrointestinal  tract)  nervous  system.  While 
abdominal vagal afferents are not required for the acute appetite-stimulatory effect of 
peripheral ghrelin [28], there is evidence that genetic blockage of ghrelin receptors in 
autonomic nerve endings leads to increased body temperature and energy expenditure as 
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well as brown adipose tissue activity [29]. This implies that peripheral actions of ghrelin or its 
receptor in autonomic nerve endings may play a role in body temperature regulation. 
 
Even though the exact cause for the isolated case of hypothermia during ghrelin 
administration has not been identified, it appears to be an isolated occurrence in a highly 
selected population (terminally ill cancer patient with cachexia). Potentially, a yet unknown 
constellation of sensitizing factors in that particular individual may have induced this severe 
drop in temperature. A similar phenomenon was not observed in our subsequent series of 
studies of ghrelin treatment in populations of mice, rats or humans. 
 
Based on our and all other available data we would still recommend careful monitoring of 
body temperature and other vital signs in clinical studies involving ghrelin administration. 
Further studies are needed to better understand the potential relevance of ghrelin action at 
receptors in the MPOA and the specific conditions under which acute and chronic ghrelin 
treatment  may  have   a  pharmacologically  or   clinically  meaningful  effect  on   central 
temperature control or cell autonomous thermogenic processes. 
 
Acknowledgements 
 
 
The skillful technical assistance of Susanne deWolf-Linder (Clinical Research Nurse 
Oncological Palliative Medicine), the staff of the Clinical Research Unit Oncology of Cantonal 
Hospital St.Gallen and of Carola Plaue (Department of Experimental Diabetology, German 
Institute of Human Nutrition) is gratefully acknowledged. Funding for J.T. is provided by 
NIH/NIDDK (5K23DK80081). 
 
 
 
 
 
 
References 
 
[1] Tschop, M., Smiley, D. L., Heiman, M. L. Ghrelin induces adiposity in rodents. Nature. 
2000,407:908-13. 
[2] Lawrence, C. B., Snape, A. C., Baudoin, F. M., Luckman, S. M. Acute central ghrelin and 
GH  secretagogues  induce  feeding  and  activate  brain  appetite  centers.  Endocrinology. 
2002,143:155-62. 
[3] Theander-Carrillo, C., Wiedmer, P., Cettour-Rose, P., Nogueiras, R., Perez-Tilve, D., 
Pfluger, P., et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest. 
2006,116:1983-93. 
[4] Asakawa, A., Inui, A., Kaga, T., Yuzuriha, H., Nagata, T., Ueno, N., et al. Ghrelin is an 
appetite-stimulatory signal from stomach with structural resemblance to motilin. 
Gastroenterology. 2001,120:337-45. 
[5] Tschop, M., Statnick, M. A., Suter, T. M., Heiman, M. L. GH-releasing peptide-2 increases 
fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti- 
related protein. Endocrinology. 2002,143:558-68. 
17 
 
[6] Tang-Christensen, M., Vrang, N., Ortmann, S., Larsen, P. J., Horvath, T., Tschoep, M. 
Ghrelin induces long lasting changes in food intake and locomotor behaviour.  Proceedings 
of the 85th Annual Meeting of the Endocrine Society, Philadelphia.2003. p. P3–94: 497 (abs). 
[7] Tang-Christensen, M., Vrang, N., Ortmann, S., Bidlingmaier, M., Horvath, T. L., Tschop, 
M. Central administration of ghrelin and agouti-related protein (83-132) increases food intake 
and decreases spontaneous locomotor activity in rats. Endocrinology. 2004,145:4645-52. 
[8]  Yasuda,  T.,  Masaki,  T.,  Kakuma,  T.,  Yoshimatsu,  H.  Centrally  administered  ghrelin 
suppresses  sympathetic  nerve  activity  in  brown  adipose  tissue  of  rats.  Neurosci  Lett. 
2003,349:75-8. 
[9] Strasser, F., Lutz, T. A., Maeder, M. T., Thuerlimann, B., Bueche, D., Tschop, M., et al. 
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related 
anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. 
Br J Cancer. 2008,98:300-8. 
[10] Tong, J., Prigeon, R. L., Davis, H. W., Bidlingmaier, M., Kahn, S. E., Cummings, D. E., et 
al.  Ghrelin  Suppresses  Glucose-Stimulated  Insulin  Secretion  and  Deteriorates  Glucose 
Tolerance in Healthy Humans. Diabetes. 2010,59:2145-51. 
[11] Cowley, M. A., Smith, R. G., Diano, S., Tschop, M., Pronchuk, N., Grove, K. L., et al. 
The distribution and  mechanism of  action of ghrelin in the CNS  demonstrates a novel 
hypothalamic circuit regulating energy homeostasis. Neuron. 2003,37:649-61. 
[12] Diano, S., Horvath, B., Urbanski, H. F., Sotonyi, P., Horvath, T. L. Fasting Activates the 
Nonhuman Primate Hypocretin (Orexin) System and Its Postsynaptic Targets. 
Endocrinology. 2003,144:3774-8. 
[13] Paxinos, G., Watson, C. The Rat Brain in Stereotaxic Coordinates. 4 ed. New York: 
Academic Press; 1998. 
[14]  Romanovsky,  A.  A.  Thermoregulation:  some  concepts  have  changed.  Functional 
architecture  of  the thermoregulatory system.  Am  J  Physiol  Regul  Integr  Comp  Physiol. 
2007,292:R37-46. 
[15]  Cannon,  B.,  Nedergaard,  J.  Brown  adipose  tissue:  function  and  physiological 
significance. Physiol Rev. 2004,84:277-359. 
[16] Zigman, J. M., Jones, J. E., Lee, C. E., Saper, C. B., Elmquist, J. K. Expression of 
ghrelin receptor mRNA in the rat and the mouse brain. J Comp Neurol. 2006,494:528-48. 
[17] Guan, X. M., Yu, H., Palyha, O. C., McKee, K. K., Feighner, S. D., Sirinathsinghji, D. J., 
et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and 
peripheral tissues. Brain Res Mol Brain Res. 1997,48:23-9. 
[18] Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., Weigle, D. S. 
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. 
Diabetes. 2001,50:1714-9. 
[19] Yildiz, B. O., Suchard, M. A., Wong, M. L., McCann, S. M., Licinio, J. Alterations in the 
dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci 
U S A. 2004,101:10434-9. 
[20] Tolle, V., Bassant, M. H., Zizzari, P., Poindessous-Jazat, F., Tomasetto, C., Epelbaum, 
J., et al. Ultradian rhythmicity of ghrelin secretion in relation with GH, feeding behavior, and 
sleep-wake patterns in rats. Endocrinology. 2002,143:1353-61. 
[21] Gluck, E. F., Stephens, N., Swoap, S. J. Peripheral ghrelin deepens torpor bouts in mice 
through the arcuate nucleus neuropeptide Y signaling pathway. Am J Physiol Regul Integr 
Comp Physiol. 2006,291:R1303-9. 
[22] Billington, C. J., Briggs, J. E., Grace, M., Levine, A. S. Effects of intracerebroventricular 
injection of neuropeptide Y on energy metabolism. Am J Physiol. 1991,260:R321-7. 
[23] Billington, C. J., Briggs, J. E., Harker, S., Grace, M., Levine, A. S. Neuropeptide Y in 
hypothalamic  paraventricular  nucleus:  a  center  coordinating  energy  metabolism.  Am  J 
Physiol. 1994,266:R1765-70. 
[24] Egawa, M., Yoshimatsu, H., Bray, G. A. Neuropeptide Y suppresses sympathetic activity 
to interscapular brown adipose tissue in rats. Am J Physiol. 1991,260:R328-34. 
[25] Wortley, K. E., Anderson, K. D., Yasenchak, J., Murphy, A., Valenzuela, D., Diano, S., et 
al. Agouti-related protein-deficient mice display an age-related lean phenotype. Cell Metab. 
2005,2:421-7. 
18 
 
[26] Brito, M. N., Brito, N. A., Baro, D. J., Song, C. K., Bartness, T. J. Differential Activation of 
the Sympathetic Innervation of Adipose Tissues by Melanocortin Receptor Stimulation. 
Endocrinology. 2007,148:5339-47. 
[27] Burdyga, G., Varro, A., Dimaline, R., Thompson, D. G., Dockray, G. J. Ghrelin receptors 
in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor 
abundance. Am J Physiol Gastrointest Liver Physiol. 2006,290:G1289-97. 
[28] Arnold, M., Mura, A., Langhans, W., Geary, N. Gut vagal afferents are not necessary for 
the  eating-stimulatory  effect  of  intraperitoneally  injected  ghrelin  in  the  rat.  J  Neurosci. 
2006,26:11052-60. 
[29] Mano-Otagiri, A., Iwasaki-Sekino, A., Nemoto, T., Ohata, H., Shuto, Y., Nakabayashi, H., 
et  al.  Genetic  suppression  of  ghrelin  receptors  activates  brown  adipocyte  function  and 
decreases fat storage in rats. Regul Pept. 2010,160:81-90. 
 
 
 
Figure legends 
 
 
 
 
Fig. 1: Ghrelin-imunoreactivity (a) and ghrelin binding (b) in rat medial preoptic area. Axon 
terminal containing ghrelin immunolabeling lay in close apposition to neurons that express c- 
fos in response to cold exposure (c and d). 
 
 
 
 
Fig. 2: Ghrelin chronically infused i.c.v. (2.5 nmol/d) increased food intake and body weight. 
Absolute food intake (A) and body weight change (B) of rats treated i.c.v. with either saline or 
2.5 nmol/d ghrelin. Data represent mean±SEM. P<0.001 (time x treatment) for both food 
intake and body weight, one-way repeated measures ANOVA. 
 
 
 
 
Fig. 3: Ghrelin chronically infused i.c.v. (2.5 nmol/d) did not change body temperature or 
locomotor activity. Body core temperature (A) and gross locomotor activity (B) of rats treated 
i.c.v. with either saline or 2.5 nmol/d ghrelin. Shown are the first 3 days following start of 
treatment. Data represent mean±SEM. 
 
 
 
 
Fig. 4: Ghrelin further increased cold induced food intake. Cumulative Food intake (24h) after 
single i.p. saline injection at 21°C (all mice) and after single i.p. injection of either saline or 
ghrelin (10 mg/kg) at 4°C ambient temperature (n=10/group). Data represent mean±SEM. * 
P<0.001 vs. saline 21°C, # P<0.05 vs. saline, saline no food access (5h) and ghrelin no food 
access (5h) at 4°C; (ANOVA, Post-hoc LSD) 
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Fig. 5: Cold induced changes in body core temperature, locomotor activity and energy 
expenditure depend on food availability, but not on ghrelin action. Body temperature, gross 
locomotor activity and total energy expenditure at 21°C (A, C and E, respectively) after single 
i.p. saline injection and during acute cold exposure after single i.p. ghrelin (10 mg/kg) or 
saline injection (B, D and F, respectively). The first 5h following injection are shown. Data 
represent mean±SEM, n=10/group. 
 
 
 
 
Fig. 6: Ghrelin induced increase of respiratory quotient depends on food availability. 
Respiratory quotient was measured at 21°C following single i.p. saline injection (A) and 
during acute cold exposure following single i.p. ghrelin (10 mg/kg) or saline injection (B). The 
whole measurement period of 23h following injection is shown. Data represent mean±SEM, 
n=10/group. 
 
 
 
 
Fig. 7: Ghrelin has no effect on body surface temperature in humans. Synthetic human 
ghrelin (0.2 and 0.6 nmol/kg/hr) or saline were infused on three separate days for a total of 
225 minutes each in 16 healthy volunteers. No difference in body surface temperature 
between ghrelin treatment and control was found (p = 0.15, two-way repeated measures 
ANOVA). Data represent mean ± SEM. 
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